P. Hegde

Oncology · Nature · 2000–2020

A researcher in the Science corpus: 11 papers; trusts 3 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom P. Hegde trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. D. Pardoll
  2. Daniel S. Chen
  3. Jérôme Galon
  4. Padmanee Sharma
  5. Nicholas McGranahan

Who trusts P. Hegde overall

  1. Yuan-Tong Liu

Papers from P. Hegde's perspective

Ordered by how strongly the researchers P. Hegde trusts endorse each paper. Same corpus, a different order for every researcher.

  1. The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
  2. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome (Science)
  3. Pembrolizumab for the treatment of non-small-cell lung cancer. (New England Journal of Medicine)
  4. PD-1 blockade in tumors with mismatch repair deficiency. (Journal of Clinical Oncology)
  5. The future of immune checkpoint therapy (Science)
  6. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (New England Journal of Medicine)
  7. Cancer immunotherapy comes of age (Nature)
  8. Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates (Journal of Clinical Oncology)
  9. An immune-active tumor microenvironment favors clinical response to ipilimumab (Cancer Immunology and Immunotherapy)
  10. Tumor Endothelium FasL Establishes a Selective Immune Barrier Promoting Tolerance in Tumors (Nature Medicine)

Their papers